Raymond James Financial Inc. Invests $42.19 Million in Haleon plc (NYSE:HLN)

Raymond James Financial Inc. acquired a new stake in Haleon plc (NYSE:HLN) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 4,422,760 shares of the company’s stock, valued at approximately $42,193,000. Raymond James Financial Inc. owned about 0.10% of Haleon as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. FMR LLC raised its position in shares of Haleon by 3.7% during the 4th quarter. FMR LLC now owns 108,827,814 shares of the company’s stock valued at $1,038,217,000 after acquiring an additional 3,909,545 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Haleon by 67.5% during the fourth quarter. Wellington Management Group LLP now owns 15,328,325 shares of the company’s stock worth $146,232,000 after purchasing an additional 6,175,835 shares during the period. Douglas Lane & Associates LLC lifted its position in shares of Haleon by 1.9% in the 4th quarter. Douglas Lane & Associates LLC now owns 8,624,149 shares of the company’s stock worth $82,274,000 after buying an additional 161,865 shares during the last quarter. Envestnet Asset Management Inc. lifted its position in shares of Haleon by 0.8% in the 4th quarter. Envestnet Asset Management Inc. now owns 7,630,307 shares of the company’s stock worth $72,793,000 after buying an additional 58,444 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Haleon by 18.3% in the 4th quarter. JPMorgan Chase & Co. now owns 6,014,903 shares of the company’s stock valued at $57,382,000 after buying an additional 930,701 shares during the period. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Stock Performance

Shares of HLN opened at $10.13 on Wednesday. Haleon plc has a 52-week low of $8.04 and a 52-week high of $10.80. The firm has a market capitalization of $45.76 billion, a PE ratio of 29.79, a P/E/G ratio of 2.82 and a beta of 0.24. The firm has a 50-day moving average price of $10.06 and a 200 day moving average price of $9.81. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44.

Haleon (NYSE:HLN) last posted its quarterly earnings data on Thursday, February 27th. The company reported $0.05 EPS for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The company had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion. On average, sell-side analysts anticipate that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The business also recently disclosed a — dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be paid a dividend of $0.1166 per share. The ex-dividend date of this dividend is Friday, April 25th. This is a positive change from Haleon’s previous — dividend of $0.05. This represents a dividend yield of 1.6%. Haleon’s dividend payout ratio (DPR) is currently 58.97%.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Morgan Stanley downgraded Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Hsbc Global Res lowered Haleon from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Haleon in a report on Monday, March 3rd. Finally, HSBC reissued a “hold” rating on shares of Haleon in a research note on Wednesday, March 5th. Six analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.